NanoLogix CEO Bret Barnhizer stated: "With the BNP(TM) kits, we believe we are on our way to establishing a new 'gold Standard' for microorganism detection that will have a revolutionary effect on medical testing, diagnosis and treatment. This production facility will enable us to capitalize on our technology and provide product to those who are rapidly becoming aware of the BNP(TM) potential".
The test kits provide users the ability for faster detection of a long list of pathogens, including E-coli, Salmonella, Listeria, Enterobacter, Staphylococcus, Anthrax and Bubonic plague.
In addition to providing ultra-fast viewing of microorganisms normally cultured on standard Petri plates, the BNP(TM) kits can be used to assist in early detection of some of the most dangerous pathogens in the world, including those that pose significant potential threats for use as bio-weapons by terrorists.
The BNP(TM) production operation is expected to create a dozen jobs in the economically depressed Youngstown, Ohio, area, with more to follow as product demand increases.
Other NNLX News:
NanoLogix recently received a substantial royalty payment for 2008 from NutraPharma, a bio-pharmaceutical company with a license on a number of NanoLogix patents.
CEO Bret Barnhizer and Director John Chatterton recently met with U.S. Representative Tim Ryan (Ohio 17th District) in Washington DC for a discussion of Federal programs related to business assistance.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, ca
|SOURCE NanoLogix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved